The purpose of this study is to determine whether the drug combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment for refractory melanoma. The study focuses on people whose melanoma has spread or whose melanoma cannot be removed with surgery (unresectable). Fianlimab is a drug called a monoclonal antibody that targets a protein found on immune cells to regulate their function. By blocking a protein called lymphocyte activation gene-3 protein (LAG-3), fianlimab may help slow or stop the growth of cancer. Cemiplimab is a type of drug called a monoclonal anti-PD1 antibody. PD-1 is a protein that acts as a “brake” on the immune system. Blocking this protein is like releasing the brakes, so the immune system can target cancer cells and destroy them. Ipilimumab is an immunotherapy drug that boosts the body’s natural defenses to fight cancer. It is a type of drug called a CTLA-4 inhibitor. By blocking the CTLA-4 protein, ipilimumab may help slow or stop the growth of cancer. Because these drugs work in different ways, researchers believe their combination may be more effective than any of the 3 drugs given alone. All study participants will receive fianlimab, cemiplimab, and ipilimumab. The use of fianlimab, cemiplimab, and ipilimumab as a combination in this study is considered experimental.
What is the full name of this clinical trial?
24-166 A: A phase 2 study of fianlimab, cemiplimab, and ipilimumab in anti-PD-1 refractory melanoma